| 书目名称 | Cancer Chemoprevention | | 副标题 | Volume 2: Strategies | | 编辑 | Gary J. Kelloff,Ernest T. Hawk,Caroline C. Sigman | | 视频video | | | 概述 | Includes supplementary material: | | 丛书名称 | Cancer Drug Discovery and Development | | 图书封面 |  | | 描述 | Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development—those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can “reasonably predict” clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate end | | 出版日期 | Book 2005 | | 关键词 | carcinoma; endoscopy; imaging; morbidity; positron emission tomography | | 版次 | 1 | | doi | https://doi.org/10.1007/978-1-59259-768-0 | | isbn_softcover | 978-1-62703-817-1 | | isbn_ebook | 978-1-59259-768-0Series ISSN 2196-9906 Series E-ISSN 2196-9914 | | issn_series | 2196-9906 | | copyright | Humana Press 2005 |
The information of publication is updating
|
|
发表于 2025-3-21 19:24:28
